Our most-read ocular surface disease coverage of 2025 highlights a growing and increasingly nuanced treatment landscape. From cyclosporine formulations designed to optimize the ocular surface and improve adherence to novel, water-free and evaporation-targeting therapies, these articles reflect continued progress in addressing both the signs and symptoms of dry eye with more patient-friendly approaches.
Cyclosporine 0.09% can quickly improve ocular surface health in dry eye patients
John Hovanesian, MD, of Harvard Eye Associates, spoke with Ophthalmology 360 about a study that found that cyclosporine 0.09% can help prepare the ocular surface ahead of cataract surgery.
Watch the full video here.
Water-free VEVYE® eye drops improve dry eye symptoms and adherence
An ophthalmologist reports that VEVYE, a water-free cyclosporine eye drop, provides rapid, well-tolerated relief of dry eye disease symptoms in clinical practice, consistent with trial data showing early improvements in corneal staining, tear production, and patient-reported outcomes. Improved comfort and adherence compared with older cyclosporine formulations were highlighted, with some benefits based on real-world experience rather than comparative trials.
Read the full article here.
Spotlight on MIEBO®
Clinical trial data show that perfluorohexyloctane ophthalmic solution (MIEBO) improves both signs and symptoms of dry eye disease associated with meibomian gland dysfunction by directly targeting tear evaporation. Across phase 3 pivotal trials, a long-term extension study, and a phase 4 study, MIEBO demonstrated consistent reductions in corneal staining and patient-reported dryness, rapid symptom relief, and a favorable safety profile with mostly mild to moderate adverse events.
Related Content
